Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Patients diagnosed with DLBCL
Age ≥18 years
Prior treatment with a polatuzumab vedotin (pola)-containing regimen and confirmed disease progression (refractory/relapsed) after this therapy.
Availability of complete electronic medical records and ability to be contacted via telephone.
Full understanding of the study, voluntary participation, and willingness to sign the informed consent form.

Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy